Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans

Molecular Immunology

Volumn 46, Issue 3, 2009, Pages 473-480

  Boxx, Gayle M ^a   Nishiya, Casey T ^a   Kozel, Thomas R ^b   Zhang, Mason X ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Alternative pathway; Antimannan antibody; C3 convertase; Candida; Complement; Fab; Factor B; Fc independent

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY;

ARTICLE; CANDIDA ALBICANS; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE MICROSCOPY; KINETICS; NONHUMAN; PRIORITY JOURNAL;

ANTIBODIES; CANDIDA ALBICANS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; KINETICS; MANNANS; RECEPTORS, FC; RECOMBINANT PROTEINS;

CANDIDA; CANDIDA ALBICANS;

EID: 57749084326     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.10.008     Document Type: Article

References (47)

1. Albar J.P., Juarez C., Vivanco-Martinez F., Bragado R., and Ortiz F. Structural requirements of rabbit IgG F(ab′)2 fragment for activation of the complement system through the alternative pathway. I. Disulfide bonds. Mol. Immunol. 18 (1981) 925-934
2. Ehrnst A. Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway. J. Immunol. 121 (1978) 1206-1212
3. Eisenberg R.A., and Schwab J.H. Arthropathic group A streptococcal cell walls require specific antibody for activation of human complement by both the classical and alternative pathways. Infect. Immun. 53 (1986) 324-330
4. Fine D.P., Marney Jr. S.R., Colley D.G., Sergent J.S., and Des Prez R.M. C3 shunt activation in human serum chelated with EGTA. J. Immunol. 109 (1972) 807-809
5. Gelfand J.A., Hurley D.L., Fauci A.S., and Frank M.M. Role of complement in host defense against experimental disseminated candidiasis. J. Infect. Dis. 138 (1978) 9-16
6. Han Y., and Cutler J.E. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63 (1995) 2714-2719
7. Han Y., Kanbe T., Cherniak R., and Cutler J.E. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun. 65 (1997) 4100-4107
8. Han Y., Kozel T.R., Zhang M.X., MacGill R.S., Carroll M.C., and Cutler J.E. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167 (2001) 1550-1557
9. Han Y., Riesselman M.H., and Cutler J.E. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 68 (2000) 1649-1654
10. Hector R.F., Domer J.E., and Carrow E.W. Immune responses to Candida albicans in genetically distinct mice. Infect. Immun. 38 (1982) 1020-1028
11. Held K., Thiel S., Loos M., and Petry F. Increased susceptibility of complement factor B/C2 double knockout mice and mannan-binding lectin knockout mice to systemic infection with Candida albicans. Mol. Immunol. 45 (2008) 3934-3941
12. Horstmann R.D., Pangburn M.K., and Muller-Eberhard H.J. Species specificity of recognition by the alternative pathway of complement. J. Immunol. 134 (1985) 1101-1104
13. Joiner K.A., Goldman R.C., Hammer C.H., Leive L., and Frank M.M. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab′)2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. J. Immunol. 131 (1983) 2563-2569
14. Jones J.M. Quantitation of antibody against cell wall mannan and a major cytoplasmic antigen of Candida in rabbits, mice, and humans. Infect. Immun. 30 (1980) 78-89
15. Kipnis T.L., Krettli A.U., and Dias D.S. Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand. J. Immunol. 22 (1985) 217-226
16. Kozel T.R., Brown R.R., and Pfrommer G.S. Activation and binding of C3 by Candida albicans. Infect. Immun. 55 (1987) 1890-1894
17. Kozel T.R., deJong B.C., Grinsell M.M., MacGill R.S., and Wall K.K. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule. Infect. Immun. 66 (1998) 1538-1546
18. Kozel T.R., MacGill R.S., Percival A., and Zhou Q. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect. Immun. 72 (2004) 209-218
19. Kozel T.R., Weinhold L.C., and Lupan D.M. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun. 64 (1996) 3360-3368
20. Kozel T.R., Wilson M.A., and Murphy J.W. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59 (1991) 3101-3110
21. Lillegard J.B., Sim R.B., Thorkildson P., Gates M.A., and Kozel T.R. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J. Infect. Dis. 193 (2006) 1589-1597
22. Lutz H.U., Fumia S., Schurtenberger C., and Alaia V. Opinion paper: Stimulation of complement amplification or activation of the alternative pathway of complement?. Mol. Immunol. 44 (2007) 3862-3865
23. Lyon F.L., Hector R.F., and Domer J.E. Innate and acquired immune responses against Candida albicans in congenic B10.D2 mice with deficiency of the C5 complement component. J. Med. Vet. Mycol. 24 (1986) 359-367
24. Mehlhop E., and Diamond M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203 (2006) 1371-1381
25. Meri S., and Pangburn M.K. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3982-3986
26. Meri T., Hartmann A., Lenk D., Eck R., Wurzner R., Hellwage J., et al. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect. Immun. 70 (2002) 5185-5192
27. Miyakawa Y., Kagaya K., Fukazawa Y., and Soe G. Production and characterization of agglutinating monoclonal antibodies against predominant antigenic factors for Candida albicans. J. Clin. Microbiol. 23 (1986) 881-886
28. Moore Jr. F.D., Austen K.F., and Fearon D.T. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J. Immunol. 128 (1982) 1302-1306
29. Mueller-Ortiz S.L., Drouin S.M., and Wetsel R.A. The alternative activation pathway and complement component C3 are critical for a protective immune response against Pseudomonas aeruginosa in a murine model of pneumonia. Infect. Immun. 72 (2004) 2899-2906
30. Nadkarni A., Kelley L.L., and Momany C. Optimization of a mouse recombinant antibody fragment for efficient production from Escherichia coli. Protein Expres. Purif. 52 (2007) 219-229
31. Pace C.N., Vajdos F., Fee L., Grimsley G., and Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4 (1995) 2411-2423
32. Pangburn M.K., and Muller-Eberhard H.J. The alternative pathway of complement. Springer Semin. Immunopathol. 7 (1984) 163-192
33. Roos A., Bouwman L.H., Munoz J., Zuiverloon T., Faber-Krol M.C., Fallaux-van den Houten F.C., et al. Functional characterization of the lectin pathway of complement in human serum. Mol. Immunol. 39 (2003) 655-668
34. Schenkein H.A., and Ruddy S. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for zymosan enhances alternative pathway activation by zymosan. J. Immunol. 126 (1981) 7-10
35. Schenkein H.A., and Ruddy S. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway. J. Immunol. 126 (1981) 11-15
36. Schreiber R.D., Pangburn M.K., Lesavre P.H., and Muller-Eberhard H.J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 3948-3952
37. Sissons J.G., Cooper N.R., and Oldstone M.B. Alternative complement pathway-mediated lysis of measles virus infected cells: induction by IgG antibody bound to individual viral glycoproteins and comparative efficacy of F(ab′)2 and Fab′ fragments. J. Immunol. 123 (1979) 2144-2149
38. Spitzer D., Mitchell L.M., Atkinson J.P., and Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179 (2007) 2600-2608
39. Steele N.P., Munson Jr. R.S., Granoff D.M., Cummins J.E., and Levine R.P. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect. Immun. 44 (1984) 452-458
40. Suzuki S. Immunochemical study on mannans of genus Candida. I. Structural investigation of antigenic factors 1, 4, 5, 6, 8, 9, 11, 13, 13b and 34. Curr. Top. Med. Mycol. 8 (1997) 57-70
41. Wachter E., and Brade V. Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica. Infect. Immun. 57 (1989) 1984-1989
42. Wurzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol. Immunol. 36 (1999) 249-260
43. Zhang M.X., and Kozel T.R. Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect. Immun. 66 (1998) 4845-4850
44. Zhang M.X., Lupan D.M., and Kozel T.R. Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect. Immun. 65 (1997) 3822-3827
45. Zhang M.X., Bohlman M.C., Itatani C., Burton D.R., Parren P.W., St Jeor S.C., et al. Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. 74 (2006) 362-369
46. Zhong Z., Burns T., Chang Q., Carroll M., and Pirofski L. Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide. Infect. Immun. 67 (1999) 4119-4127
47. Zipfel P.F., Wurzner R., and Skerka C. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol. Immunol. 44 (2007) 3850-3857